We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
05/12/2016 09:27 | Thanks for the down-tick. You know I am right but you don't like what I say. | minerve | |
05/12/2016 09:23 | Next it will be full-scale support of boob-job, tattoos and Botox reversals. Still the kids with the rare cancers can die. | minerve | |
05/12/2016 09:19 | People are very quick to target obese people but many have hormonal and thyroid disorders that don't help their condition. Society ostracizes them leading to anxiety and poor self-esteem in which they then seek more comfort in food. And the cycle repeats itself. Same with mental health conditions. People would generally be healthier and savings would be had by the NHS if society was more accepting of people who didn't fit the current fad of gay, fit and 'plastic looking' like effigies of Ken & Barbie. | minerve | |
05/12/2016 09:16 | Yup as with smoking which was nearly 40 a day at one point, 15 years ago now. Anyway I suppose we all have faults, however I think the future of healthcare will see some type of rationing, if your BMI is over a certain level you already do not qualify for certain operations - in fairness there is often good clinical reasons for this, patient safety with anaesthetics etc. | essentialinvestor | |
05/12/2016 09:12 | EI - the magic word is "previously" - so you have obviously done something about it | ttg100 | |
05/12/2016 09:10 | What about the health freaks? Breaking limbs, cycling accidents and so on. They are going to look really funny in a decade or so lying in hospital dying of nothing. | minerve | |
05/12/2016 09:03 | ttg, my point really is where do you draw the line. I've been overweight previously so not mentioning it in a holier than thou way. | essentialinvestor | |
05/12/2016 09:01 | Just have a walk round places like Asda and see how many extremely obese people pick up trays of doughnuts - as a type 1 diabetic with no choice it makes me really really angry !!!!! | ttg100 | |
05/12/2016 08:55 | My other half arranged social care last week for lady born in 1960, who due to morbid obesity suffers from chronic leg ulcers, COPD and needs an oxygen supply at home on hand. Two careers seven days a week for 30 minutes morning and evening, all paid for by the state. On disability benefit, entirely self inflicted due to lifestyle choices. | essentialinvestor | |
04/12/2016 14:41 | Obesity treatments are going to dwarf anything else the way waistlines are going. The oncology compounds mentioned in Fierce Pharma cost between $70,000-$170,000 per course of treatment. The medium improvement in overall survival rates was 2.1 months. Only one drug was found to improve quality of life. Looks like an interesting open tomorrow. | essentialinvestor | |
04/12/2016 14:12 | There is a damming report in Fierce Pharma on the lack of effectiveness of many oncology drugs approved between 2008-2012. It is shocking read, particularly in the context of the huge cost of these treatments. PREP to be made available on the NHS in a 3 year 10,000 person trial, the ViiV Prep product has just entered Phase 111 from memory. | essentialinvestor | |
04/12/2016 08:46 | https://www.theguard | xtrmntr | |
02/12/2016 21:56 | EI, sorry missed that, scanned too quickly! | ianood | |
02/12/2016 19:36 | Ian, yes as mentioned they offered an undisclosed price cut, so their additional cost/benefit data was based on this. It underscores the point mentioned yesterday about pharma having to increasingly show cost/benefit for approval of new medications. With their Lupus treatment NICE reportedly only gave approval following 3 price cuts by GSK. | essentialinvestor | |
02/12/2016 17:33 | EI - and the price that the NHS is paying has not bee disclosed. | ianood | |
02/12/2016 14:33 | May have been mentioned- NICE issued draft approval for Nucala this week changing their previous decision. GSK provided more data on cost effectiveness and offered an undisclosed price cut. The standard cost is £840 per dose. More than 100,000 people in the UK suffer from asthma that cannot be treated with with regular medicines. A dose of Nucela is given every 4 weeks. Although the standard price appears high, would think many of those 100,000 patients will end up in A&E on a regular basis, some requiring inpatient monitoring and treatment. See what happens Sunday, Monday may be interesting!. | essentialinvestor | |
02/12/2016 11:42 | Agreed, Waiting for monday here and on AZN. | philo124 | |
02/12/2016 10:00 | Perhaps worth leaving some for next week Essential - just in case of Italy going pear shape! 😉 | minerve | |
02/12/2016 09:59 | Morning everyone . GSK and BATS this morning for me. | philanderer | |
02/12/2016 09:57 | My better half deals with COPD cases almost daily in her work, it really is a pernicious illness and also progressive. Added some more GSK near the open and also some DGE. | essentialinvestor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions